ARKG.US ARK Genomic Revolution ETF
- Total assets
- 1.99B
- Expense ratio
- 0.71%
- Dividend yield
- -
- 1-year return
- +54.78%
- Holdings
- 32
- Since
- 2014
Fund data as reported by the issuer, updated Nov 14, 2026. Total assets are in the fund's base currency.
What does ARKG.US invest in?
- Mostly US stocks (87.5%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (91.3%)
- Top 3 holdings: 26.6% of the fund
Asset allocation
- US stocks 87.5%
- Non-US stocks 8.1%
- Cash 0.2%
Top holdings
- Tempus AI, Inc. Class A Common Stock 10.43%
- 10X Genomics Inc 8.28%
- Twist Bioscience Corp 7.87%
- Absci Corp 5.55%
- Crispr Therapeutics AG 5.11%
ARK Genomic Revolution ETF performance
Sharpe ratio 0.74- This year
- +51.00%
- 1 year
- +54.78%
- 3 years
- +22.67%
- 5 years
- -9.42%
Volatility 42.2% over 1 year and 39.1% over 3 years. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
ARKG.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About ARK Genomic Revolution ETF
The fund is an actively-managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution (Genomics Revolution Companies). It is non-diversified.
Full fund profileARK Genomic Revolution ETF top holdings
59.2% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Tempus AI, Inc. Class A Common Stock TEM.US | Healthcare | United States | 10.43% |
| 10X Genomics Inc TXG.US | Healthcare | United States | 8.28% |
| Twist Bioscience Corp TWST.US | Healthcare | United States | 7.87% |
| Absci Corp ABSI.US | Healthcare | United States | 5.55% |
| Crispr Therapeutics AG CRSP.US | Healthcare | United States | 5.11% |
| Guardant Health Inc GH.US | Healthcare | United States | 4.90% |
| Natera Inc NTRA.US | Healthcare | United States | 4.40% |
| Eli Lilly and Company LLY.US | Healthcare | United States | 4.35% |
| Illumina Inc ILMN.US | Healthcare | United States | 4.18% |
| Beam Therapeutics Inc BEAM.US | Healthcare | United States | 4.08% |
The 10 largest of 32 holdings.
ARKG.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
ARKG.US regional exposure
- North America91.3%
- Europe Developed5.1%
- United Kingdom2.8%
Share of the stocks in the fund.
Company size
Average market cap 7.46B- Mega cap4.6%
- Medium cap18.0%
- Small cap37.5%
- Micro cap29.5%
ARK Genomic Revolution ETF fund profile
- Fund name
- ARK Genomic Revolution ETF
- Ticker
- ARKG.US
- Exchange
- USA Stocks
- Issuer
- ARK ETF Trust
- Index tracked
- -
- Category
- Healthcare Equity
- Domicile
- United States
- Inception date
- Oct 31, 2014
- Trading currency
- USD
- Expense ratio
- 0.71%
- Annual turnover
- 0.3%
About ARK Genomic Revolution ETF
The fund is an actively-managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution (Genomics Revolution Companies). It is non-diversified.